Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

What dosage were you prescribed daily?

Have any of the following side effects occurred? (Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Merck Saw Vioxx Risk While FDA Hid Data: Grassley

Oct 7, 2004 | Investor's Business Daily

Click here for Free Vioxx Lawsuit Case Evaluation

The U.S. Food and Drug Administration tried to cover up a study done by an FDA employee that showed a cardiac risk linked to Merck's (MRK) arthritis drug Vioxx, Sen. Charles Grassley said Thursday.

"It seems that while Merck was taking a fresh look at its clinical data in search of trouble, the [FDA] was challenging its own researcher," said Grassley, R-Iowa, chairman of the Senate Finance Committee.

The committee is investigating how the FDA reviews drugs for safety. The investigation comes after disclosure of health risks associated with Vioxx and with the use of anti-depressants in children.

In a statement, Grassley said that his committee found that FDA staffer David Graham led a study into Vioxx's cardiac risks, but that Graham was threatened and intimidated into keeping his findings quiet.

After failing to persuade Graham to water down his study's results, Grassley charged, Graham's supervisor wrote that Merck had to be advised of the newly discovered safety risk before it became public.

Merck's long-term study of Vioxx for the drug's use in treating colon polyps was ultimately halted when an increased cardiac risk was found. The company pulled its drug from the market last week, sending the firm's stock into a tailspin.

FDA officials were unavailable for comment.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo